Accès ouvert déclaré
2023
other
Data from Confirmation of 5p12 As a Susceptibility Locus for Progesterone-Receptor–Positive, Lower Grade Breast Cancer
Roger L. Milne, Ellen L. Goode, Montserrat García‐Closas, Fergus J. Couch, Gianluca Severi, Rebecca Hein, Zachary Fredericksen, Núria Malats, M. Pilar Zamora, José Ignacio Arias Pérez, Javier Benı́tez, Thilo Dörk, Peter Schürmann, Johann H. Karstens, Peter Hillemanns, Angela Cox, Ian W. Brock, Graeme Elliot, Simon S. Cross, Sheila Seal, Clare Turnbull, Anthony Renwick, Nazneen Rahman, Chen‐Yang Shen, Jyh‐Cherng Yu, Chiun‐Sheng Huang, Ming‐Feng Hou, Børge G. Nordestgaard, Stig E. Bojesen, Charlotte Lanng, Grethe Grenaker Alnæs, Vessela N. Kristensen, Anne-Lise Børrensen-Dale, John L. Hopper, Gillian S. Dite, Carmel Apicella, Melissa C. Southey, Diether Lambrechts, Betül T. Yesilyurt, Giuseppe Floris, Karin Leunen, Suleeporn Sangrajrang, Valérie Gaborieau, Paul Brennan, James McKay, Jenny Chang‐Claude, Shan Wang‐Gohrke, Paolo Radice, Paolo Peterlongo, Siranoush Manoukian, Monica Barile, Graham G. Giles, Laura Baglietto, Esther M. John, Alexander Miron, Stephen J. Chanock, Jolanta Lissowska, Mark E. Sherman, Jonine D. Figueroa, Natalia Bogdanova, Natalia Antonenkova, Iosif V. Zalutsky, Yuriy Rogov, Peter A. Fasching, Christian Bayer, Arif B. Ekici, Matthias W. Beckmann, Hermann Brenner, Heiko Müller, Volker Arndt, Christa Stegmaier, Irene L. Andrulis, Julia A. Knight, Gord Glendon, Anna Marie Mulligan, Vesa Kataja, Veli‐Matti Kosma, Jaana M. Hartikainen, Alfons Meindl, Joerg Heil, Claus R. Bartram, Rita K. Schmutzler, Gilles D. Thomas, Robert N. Hoover, Olivia Fletcher, Lorna J. Gibson, Isabel dos‐Santos‐Silva, Julian Peto, Stefan Nickels, Dieter Flesch‐Janys, Hoda Anton‐Culver, Argyrios Ziogas, Elinor J. Sawyer, Ian Tomlinson, Michael J. Kerin, Nicola Miller, Marjanka K. Schmidt, Annegien Broeks, Laura van ‘t Veer, Rob A.�E.�M. Tollenaar, Paul D.P. Pharoah, Alison M. Dunning, Karen A. Pooley, Frederik Marmé, Andreas Schneeweiß, Christof Sohn, Barbara Burwinkel, Anna Jakubowska, Jan Lubiński, Katarzyna Jaworska, Katarzyna Durda, Daehee Kang, Keun-Young Yoo, Dong‐Young Noh, Sei‐Hyun Ahn, David J. Hunter, Susan E. Hankinson, Peter Kraft, Sara Lindström, Jonathan Beesley, Ute Hamann, Volker Harth, Christina Justenhoven, Robert Winqvist, Katri Pylkäs, Arja Jukkola‐Vuorinen, Mervi Grip, Maartje J. Hooning, Antoinette Hollestelle, Rogier A. Oldenburg, Madeleine M.A. Tilanus‐Linthorst, Э. К. Хуснутдинова, Marina Bermisheva, Darya Prokofieva, Albina Farahtdinova, Janet E. Olson, Xianshu Wang, Manjeet K. Humphreys, Qin Wang, Georgia Chenevix‐Trench, Douglas F. Easton
0Citations signalées, ce qui n’est pas une note de qualité
0Institutions déclarées
0Pays d’affiliation déclarés
Le résumé fourni par la source
Abstract Background: The single-nucleotide polymorphism (SNP) 5p12-rs10941679 has been found to be associated with risk of breast cancer, particularly estrogen receptor (ER)-positive disease. We aimed to further explore this association overall, and by tumor histopathology, in the Breast Cancer Association Consortium. Methods: Data were combined from 37 studies, including 40,972 invasive cases, 1,398 cases of ductal carcinoma in situ (DCIS), and 46,334 controls, all of white European ancestry, as well as 3,007 invasive cases and 2,337 controls of Asian ancestry. Associations overall and by tumor invasiveness and histopathology were assessed using logistic regression. Results: For white Europeans, the per-allele OR associated with 5p12-rs10941679 was 1.11 (95% CI = 1.08–1.14, P = 7 × 10−18) for invasive breast cancer and 1.10 (95% CI = 1.01–1.21, P = 0.03) for DCIS. For Asian women, the estimated OR for invasive disease was similar (OR = 1.07, 95%CI = 0.99–1.15, P = 0.09). Further analyses suggested that the association in white Europeans was largely limited to progesterone receptor (PR)-positive disease (per-allele OR = 1.16, 95% CI = 1.12–1.20, P = 1 × 10−18 vs. OR = 1.03, 95% CI = 0.99–1.07, P = 0.2 for PR-negative disease; Pheterogeneity = 2 × 10−7); heterogeneity by ER status was not observed (P = 0.2) once PR status was accounted for. The association was also stronger for lower grade tumors [per-allele OR (95% CI) = 1.20 (1.14–1.25), 1.13 (1.09–1.16), and 1.04 (0.99–1.08) for grade 1, 2, and 3/4, respectively; Ptrend = 5 × 10−7]. Conclusion: 5p12 is a breast cancer susceptibility locus for PR-positive, lower grade breast cancer. Impact: Multicenter fine-mapping studies of this region are needed as a first step to identifying the causal variant or variants. Cancer Epidemiol Biomarkers Prev; 20(10); 2222–31. ©2011 AACR.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Data from Confirmation of 5p12 As a Susceptibility Locus for Progesterone-Receptor–Positive, Lower Grade Breast Cancer
- Date Crossref
- 31/03/2023
- Éditeur
- American Association for Cancer Research (AACR)
- Type
- posted-content
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Les sujets associés
Estrogen and related hormone effectsBRCA gene mutations in cancerHER2/EGFR in Cancer Research